Similarly, EZH2 inhibitors abrogated the increase of H3K27me3 levels on the promoter of CCL2 to increase its transcription and secretion in breast cancer, which induced M2 macrophage polarization and recruitment in the TME. Here, EZH2 is linked to breast carcinoma.